MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

294,64

09-мая-25 16:45:00

15 мин. задержка

Акции

-4,93

-1,65%

Сегодняшний диапазон

291,16 - 307,49

ISIN

N/A

Источник

NASDAQ

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

30 окт 2024 08:00:22 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

21 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

18 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

02 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

01 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

30 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

26 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

07 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

02 авг 2024 07:00:21 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

24 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

06 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

29 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Statement on the Passing of Dr. Stephen Harrison

24 апр 2024 16:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

23 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

09 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

18 мар 2024 23:58:56 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Proposed Public Offering

18 мар 2024 16:04:05 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.